Kalohexis
Kalohexis is a clinical-stage biotechnology company developing proprietary peptide therapeutics targeting central MC3R/MC4R receptors for metabolic disorders, with lead programs in Phase 1 for obesity (710GO) and Phase 2 for cancer cachexia (mifomelatide). It is a pre-revenue spin-out of Endevica Bio headquartered in Northbrook, Illinois.
- Company typePrivate
- Founded2026
- HeadquartersNorthbrook, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Kalohexis does
Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides designed to drug central melanocortin-3 and melanocortin-4 (MC3R/MC4R) receptors to treat metabolic disorders. The company was spun out of Endevica Bio in March 2026 and is headquartered in Northbrook, Illinois, operating as Kalohexis, LLC (Delaware). Its lead asset 710GO is an oral dual MC3R/MC4R agonist currently in a Phase 1 clinical trial in Australia enrolling approximately 100 healthy overweight or obese volunteers; preclinical data report 11.7–11.8% body weight loss in nonhuman primates over 13–15 weeks with lean-mass preservation, limited rebound after treatment cessation, and no gastrointestinal adverse events. Its second lead asset, mifomelatide (TCMCB07), is a dual MC3R/MC4R antagonist in a Phase 2 trial (Paradox, NCT06937177) for cancer cachexia in patients with advanced colorectal cancer, an indication with no FDA-approved therapies in the US. The pipeline additionally includes preclinical MC4R-selective and MC3R-selective agonist candidates targeting type 2 diabetes, MASH, opioid use disorder, sarcopenia, PCOS, and related metabolic indications.
The company's technology relies on proprietary peptide design optimized for blood-brain barrier penetration and central receptor engagement, developed over more than a decade by the Endevica Bio scientific team. Underlying differentiation is the dual-receptor mechanism, which the company positions as overcoming the safety and efficacy limitations of earlier MC4R-selective approaches and of GLP-1-based obesity therapies (poor tolerability, lean-mass loss, weight rebound). Development activities are conducted through clinical research sites with CRO support, including a WuXi Clinical partnership for the Phase 2 Paradox trial.
Kalohexis operates a pre-revenue pharmaceutical development model. Revenue generation is contingent on successful clinical advancement, regulatory approval, and commercialization of pipeline assets; pricing for any approved therapeutics would be set at the time of market launch. Go-to-market is the traditional biotech pharmaceutical pathway (wholesalers, hospital/specialty pharmacies, direct provider ordering) upon commercialization, and near-term commercial focus is on scientific publication, conference presentation (ENDO, AACR), and corporate communications to build credibility with investors and the medical community. Kalohexis shares leadership with Endevica Bio (CEO Russell Potterfield, CMSO Dr. Daniel Marks) and has added CFO Tony Mitchell and Director of Corporate Strategy Xuan Hui in 2026 to support capital formation and pipeline expansion.
Kalohexis firmographics
Firmographics- Name
- Kalohexis
- Legal name
- Kalohexis, LLC
- Website
- https://kalohexis.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kalohexis is a clinical-stage biotechnology company developing proprietary peptide therapeutics targeting central MC3R/MC4R receptors for metabolic disorders, with lead programs in Phase 1 for obesity (710GO) and Phase 2 for cancer cachexia (mifomelatide). It is a pre-revenue spin-out of Endevica Bio headquartered in Northbrook, Illinois.
- Ownership category
- akta.pro rank
Kalohexis industry classification
Industry- Product category
- Metabolic Disease Peptide Therapeutics
- akta.pro primary industry
- Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)
- akta.pro secondary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where Kalohexis is headquartered
LocationHeadquarters
- HQ city
- Northbrook
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kalohexis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development: As a clinical-stage biotechnology company, Kalohexis is in the pre-revenue stage of development. The company is advancing two lead therapeutic candidates through clinical trials: 710GO for obesity (Phase 1) and mifomelatide for cancer cachexia (Phase 2). Revenue generation is contingent on successful clinical development, regulatory approval, and commercialization of these pipeline assets.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Kalohexis product offering
Product offeringCore offering
Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides that target the central melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) to treat metabolic disorders. Its lead clinical assets are 710GO, an oral dual MC3R/MC4R agonist for general obesity currently in Phase 1 testing in Australia, and mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist for cancer cachexia currently in Phase 2 (Paradox trial, NCT06937177) for advanced colorectal cancer. The pipeline also includes preclinical MC4R-selective and MC3R-selective agonist programs targeting additional metabolic indications such as type 2 diabetes, MASH, opioid use disorder, sarcopenia, and polycystic ovary syndrome.
Product overview
Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides designed to safely and effectively modulate central melanocortin-3 and -4 receptors (MC3R/MC4R) to treat metabolic disorders. The company's portfolio consists of two lead clinical-stage assets: 710GO, an oral dual MC3R/MC4R agonist for general obesity currently in Phase 1 trials, and mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist for cancer cachexia in Phase 2 development. Beyond these lead programs, the pipeline includes first-in-class MC4R-selective and MC3R-selective agonists targeting additional metabolic indications such as type 2 diabetes, metabolic dysfunction-associated steatohepatitis, opioid use disorder, sarcopenia, and polycystic ovary syndrome. The company operates as a single product/platform entity focused entirely on melanocortin-based peptide therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- 710GO An oral dual MC3R/MC4R agonist therapeutic peptide being evaluated in Phase 1 clinical trials as a next-generation treatment for general obesity. It activates the central melanocortin system to change the metabolic set point, inducing healthier and more durable weight loss while preserving lean mass and avoiding common side effects of GLP-1 agonists.
- Mifomelatide (TCMCB07 / B07) A dual MC3R/MC4R antagonist therapeutic peptide being evaluated in Phase 2 clinical trials (Paradox trial, NCT06937177) to prevent and treat cancer cachexia in patients with advanced cancers. It targets the central melanocortin system to prevent unintentional weight loss and preserve muscle and fat mass during chemotherapy.
- MC4R-Selective Agonists (pipeline program) First-in-class MC4R-selective agonist candidates in preclinical development with potential to address multiple metabolic indications including type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), opioid use disorder, sarcopenia, polycystic ovary syndrome (PCOS), muscle retention adjuvant, and menopausal weight maintenance.
- MC3R-Selective Agonists (pipeline program) First-in-class MC3R-selective agonist candidates in preclinical development targeting additional metabolic disorders with significant unmet medical needs.
Quantifiable outcome
- 11.7% body weight loss at 13 weeks in diet-induced obese nonhuman primates treated with 710GO
- +5 more outcomes
Companies that use Kalohexis
Customer profileSegments2 records
Ideal customer profiles3 records
Kalohexis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Kalohexis partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- WuXi ClinicalcoreWuXi Clinical is partnered with Kalohexis (formerly Endevica Bio) for the Phase 2 clinical trial of mifomelatide (TCMCB07) for cancer cachexia. The trial includes 20 sites and 100 patients diagnosed with stage 4 metastatic colorectal cancer. WuXi Clinical provides clinical research services supporting the trial administration and patient enrollment.
- Endevica BiocoreEndevica Bio spun out Kalohexis in March 2026 to advance clinical development of the melanocortin-based therapeutic pipeline. Endevica Bio, a world leader in discovery of first-in-class synthetic peptidomimetics, had developed the core technology and pipeline assets over more than a decade. Kalohexis now administers ongoing clinical trials including the Phase 2 Paradox trial (NCT06937177) initiated by Endevica Bio. Kalohexis leadership includes Endevica Bio executives.
Scale indicators5 records
Recent moves7 records
Expansion highlights4 records
Kalohexis competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Kalohexis social profiles
Digital presenceKalohexis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kalohexis leadership team
Management profileNumber of profiles
Profiles6 records
Kalohexis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kalohexis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kalohexis
What does Kalohexis do?
Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides that target the central melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) to treat metabolic disorders. Its lead clinical assets are 710GO, an oral dual MC3R/MC4R agonist for general obesity currently in Phase 1 testing in Australia, and mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist for cancer cachexia currently in Phase 2 (Paradox trial, NCT06937177) for advanced colorectal cancer. The pipeline also includes preclinical MC4R-selective and MC3R-selective agonist programs targeting additional metabolic indications such as type 2 diabetes, MASH, opioid use disorder, sarcopenia, and polycystic ovary syndrome.
Is Kalohexis a public or private company?
Kalohexis is a private company. It is classified as corporate owned and is currently operating.
When was Kalohexis founded?
Kalohexis was founded in 2026. It employs 11 to 50 people.
Where is Kalohexis based?
Kalohexis is headquartered in Northbrook, United States, in the North America region.
How does Kalohexis make money?
One revenue line is on record: pharmaceutical Development.
Does Kalohexis have an API?
No public API is recorded for Kalohexis.
What industry is Kalohexis in?
Kalohexis's product category is Metabolic Disease Peptide Therapeutics. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals.